Health & Biotech

Dr Boreham’s Crucible: the story of Clinuvel, an Australian triumph

October 20, 2019October 20, 2019 | Tim Boreham

Health & Biotech

The Health Kick Podcast with Tim Boreham: Anatara Lifesciences

October 16, 2019October 16, 2019 | Tim Boreham

Health & Biotech

Dr Boreham’s Crucible: Recce Pharmaceuticals, the emerging superbug killer

October 13, 2019October 14, 2019 | Tim Boreham

Health & Biotech

The Health Kick Podcast with Tim Boreham: Kazia Therapeutics

October 9, 2019October 9, 2019 | Tim Boreham

Health & Biotech

Dr Boreham’s Crucible: Actinogen on the mend after a near-death experience

October 6, 2019October 6, 2019 | Tim Boreham

Health & Biotech

The Health Kick Podcast with Tim Boreham: BioScience Managers

October 2, 2019October 2, 2019 | Tim Boreham

Health & Biotech

Dr Boreham’s Crucible: Suda shows far more promise than its ‘penny-dreadful’ status suggests

September 29, 2019September 30, 2019 | Tim Boreham

Health & Biotech

The Health Kick Podcast with Tim Boreham: Oventus Medical

September 25, 2019September 25, 2019 | Tim Boreham

Health & Biotech

Dr Boreham’s Crucible: PharmAust wants a piece of the +$US10.2b pet drug market

September 22, 2019September 22, 2019 | Tim Boreham

Health & Biotech

Dr Boreham’s Crucible: Imagion gears up for human breast cancer trials, but market value falls way short of peers

September 16, 2019September 15, 2019 | Tim Boreham

Health & Biotech

Dr Boreham’s Crucible: Antisense wants to conquer the less crowded DMD market

September 9, 2019September 8, 2019 | Tim Boreham

Health & Biotech

Dr Boreham’s Crucible: What Anatara needs for its diarrhoea treatment to be more than just snake oil

September 2, 2019September 1, 2019 | Tim Boreham